Topical beta-adrenergic antagonists and quinidine. A risky interaction.
Higginbotham
E J
EJ
D000284:Administration, Oral; D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D019389:Cytochrome P-450 CYP2D6; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D005080:Exercise Test; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors* / Q000235:genetics; D009883:Ophthalmic Solutions; D011802:Quinidine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D013999:Timolol / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D009883:Ophthalmic Solutions; D013999:Timolol; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D019389:Cytochrome P-450 CYP2D6; D011802:Quinidine